Johnson & Johnson has launched a late-stage trial for its second COVID-19 vaccine, a report said Monday.
The New Jersey-based drugmaker had already been conducting a stage-three trial for a vaccine that is administered in a single dose. This new late-stage trial is for a second Johnson & Johnson vaccine that involves two doses, according to the website BioPharma-Reporter.
The new trial will try to determine how effective the second dose may be in extending immunity, the site said.
Testing on J&J’s single-dose vaccine began in September and involves 60,000 people from the US, Mexico, South Africa and several countries in South America.
The newly launched two-dose immunization trial has 30,000 participants from countries including the US, Britain, France, Germany, Spain and the Philippines.
The news comes as a second coronavirus vaccine has shown remarkable results from its stage-three trial.
That vaccine, developed by Moderna, appears to be nearly 95 percent effective based on test results, the company announced